Premium
SSRIs in combination with clopidogrel
Author(s) -
Lam Y. W. Francis
Publication year - 2015
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30043
Subject(s) - clopidogrel , cyp2c19 , prodrug , medicine , antiplatelet drug , active metabolite , pharmacology , drug , ticlopidine , platelet , metabolite , platelet aggregation , platelet aggregation inhibitor , cardiology , metabolism , aspirin , cytochrome p450
Clopidogrel is an antiplatelet drug commonly used to inhibit platelet aggregation after acute coronary events and interventions. It is a prodrug that requires CYP2C19‐mediated metabolism to its active metabolite. Patients with genetic deficiency or low enzyme activity of CYP2C19 would experience reduced effectiveness of clopidogrel, and in these patients alternative antiplatelet therapy should be considered. 1